Synopsis of recent research by authors named "Anna-Maria Langkilde"
- Anna-Maria Langkilde's recent research predominantly focuses on the effects of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on kidney function and heart failure, particularly in populations with chronic kidney disease and differing ejection fractions.
- Findings from her studies indicate that dapagliflozin not only offers benefits in reducing albuminuria and managing cardiovascular risks in patients with heart failure but also highlights the distinct clinical responses in various demographics, such as Asian populations versus non-Asian counterparts.
- Additionally, her analysis on the impact of ambient heat exposure on kidney function in chronic kidney disease patients suggests a potential exacerbating factor for health risks, emphasizing the need to address environmental influences in clinical outcomes.
